Abstract
The recent spread of COVID-19 across the U.S. led to concerted efforts by states to “flatten the curve” through the adoption of stay-at-home mandates that encourage individuals to reduce travel and maintain social distance and indeed using data on travel activity we find that residents start reducing mobility early in most states. Combining data on changes in travel activity with COVID-19 health outcomes and variation in state policy adoption, we characterize the direct impact of stay-at-home mandates on mobility and social distancing and link these behavioral changes to health benefits. We find evidence of dramatic declines in mobility nationwide prior to the adoption of statewide mandates. Despite these early reductions, we find that statewide stay-at-home policies induced “mandate effects” of between 4.1 and 5.9 percentage point declines relative to pre-COVID-19 levels for the first four states to introduce such policies. These effects persist when considering all states’ mandates and alternate estimation strategies that account for states’ differences in travel behavior prior to policy adoption. Using previous changes in mobility, we find significant effects on current mortality, with 1% reductions in visits to non-essential businesses weeks prior being associated with 9.2 fewer deaths per 100 million per day, corresponding with over 74,000 lives saved nationwide and resulting economic benefits between $249-$745 billion for observed behavioral changes in March and April. Observed reductions in mobility indeed contribute to flattening the curve and reduce the strain on the medical system during those two months. Our findings provide evidence that statewide stay-at-home ordinances induce additional social distancing, and ultimately attenuate the negative health consequences of COVID-19, revealing themselves as important policy tools in the fight against pandemic. Further, substantial reductions in mobility prior to state-level policies convey important policy implications.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used for this analysis are from Unacast, Health Data are from the COVID 19 Tracking project, and policy data from The New York Times, and COVID-19 US state policy databases.
